Abstracts

Citation

Michael Boivin, Miriam Chernoff, Jane Lindsey, Bonnie Zimmer, Barbara Laughton, Celeste Joyce, Katie McCarthy, Pim Brouwers, Patrick Jean-Philippe, Sonia Lee, Joan Coetzee, Avy Violari, Mark Cotton, Paul Palumbo. Initial findings from IMPAACT P1104s: a neuropsychological evaluation of HIV-infected and uninfected children in sub-Saharan Africa. Presented at: 7th International Workshop on HIV Pediatrics 2015.

Citation

JA Nelson, A Fokar, MG Hudgens, KJ Compliment, JT Hawkins, G Tegha, DD Kamwendo, D Kayira, IA Mofolo, AP Kourtis, DJ Jamieson, CM Van Der Horst, SA Fiscus. Frequent Nevirapine Resistance in Infants Infected by HIV-1 via Breastfeeding while on Nevirapine Prophylaxis: Results of the BAN Study. Presented at: CROI 2015.

Citation

S Nachman, E Andersen-Nissen, A Gartland, J Hural, MJ McElrath, Z Shi, J Ishmukhamedov, C DiazGranados, C Worrell, P Jean-Philippe, M Cotton, L Farlie, A Violari, The P1113 Study Team. IMPAACT P1113/Aeras C-015-404: Phase I/II Study of H4-IC31 in BCG-Primed Infants. Presented at: TB Vaccines Fourth global Forum.

Citation

Diana F. Clarke, Edward P. Acosta, Matthew Rizk, Yvonne Bryson, Stephen A. Spector, Lynne Mofenson, Mary Elizabeth Smith, Hedy Teppler, Carolee Welebob, Mae Cababasay, Bobbie Graham, Kat Richards, Mark Mirochnick , the P1110 Protocol Team. Raltegravir (RAL) pharmacokinetics (PK) and safety in HIV-1 exposed neonates at high risk of infection (IMPAACT P1110). Presented at: IAS 2015; 2015 Jul 20.

Citation

Christy Beneri, Soyeon Kim, Lisa Aaron, Patrick Jean-Philippe, Sharon Nachman. Assessment of NIH clinical case definitions for TB diagnostics research evaluation using the IMPAACT P1041 study data. Presented at: World TB Day Symposium: Countdown to 2015; 2014 Mar 24.

Citation

C. R. Tamandjou Tchuem, T. Maponga, M. F. Cotton, E. Nel, R. Tedder, W. Preiser, C. D. Mitchell, M. I. Andersson. A study of the prevalence of hepatitis B virus infection in the infants of HIV-infected mothers in South Africa. Presented at: 16th International Conference of Infectious Diseases; 2014 Apr 05.

Citation

RM Viani, C Alvero, T Fenton, E Acosta, R Hazra, E O'Gara, B Heckman, D McCarty-Steimers, S Min, A Wiznia. Safety and Efficacy of Dolutegravir in HIV Treatment-Experienced Adolescents: 48-Week Results. Presented at: CROI 2014; 2014 Mar 04.

Citation

J.A. Shepherd, B. Fan, C. Powers, L. Stranix-Chibanda, M.G. Fowler, L.A. DiMeglio, C. Mukwasi, K. George , G. Siberry. Novel “3-6” infant DXA scanning and analysis protocols to isolate movement and other artifacts.

Citation

Allison Agwu, Meredith Warshaw, George Siberry, Ann Melvin, Elizabeth McFarland, Andrew Wiznia, Lee Fairlie, Sandra Boyd, Hans Spiegel, Elaine Abrams, Vincent Carey for the P1094 Study Team. Immunologic Outcomes of a Randomized Controlled Trial of 3TC/FTC Monotherapy Compared to Continuing Failing cART as a Bridging Antiretroviral Strategy in Persistently Non-adherent HIV-infected Youth Harboring the M184V Resistance Mutation: Results from the IMPAACT P1094 Trial. Presented at: Pediatric Meeting and AIDS Conference.

Citation

Hedy Teppler, Brenda Homony, Carolee Welebob, Xia Xu, Matthew Rizk, Elizabeth Rhee. Raltegravir Pediatric Development: New Options for Treating the Youngest Children with HIV. Presented at: International Pediatric HIV Workshop 2014.